Olmutinib

Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC[1][2].

Product Specifications

CAS Number

[1353550-13-6]

Product Name Alternative

HM61713; BI 1482694

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Olmutinib.html

Purity

99.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C=CC(NC1=CC=CC(OC2=C3C(C=CS3)=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1)=O

Molecular Formula

C26H26N6O2S

Molecular Weight

486.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Kim ES, et al. Olmutinib: First Global Approval. Drugs. 2016 Jul;76 (11) :1153-7.|[2]Mohamed W. Attwa, et al. Detection and characterization of olmutinib reactive metabolites by LC‐MS/MS: Elucidation of bioactivation pathways. Journal of Separation science. 18 November 2019.